Biotech financing: Will ImaRx break the IPO slump?
(UPDATED: See below.)
It’s been a long, barren summer for biotech IPOs, but ImaRx, the blood-clot company we featured here, finally managed to bull its way into the public markets. The company, which withdrew an earlier $75 million IPO and lowered its offering price on the current… Continue Reading
Amicus Therapeutics prices IPO, raising up to $86M
Cranbury, N.J.-based Amicus Therapeutics priced its IPO shares at $15, right in the middle of its expected $14 to $16 range, an offering that could raise up to $86.3 million in gross proceeds if it sells all 5.75 million shares available. Here is the company’s… Continue Reading
Amicus Therapeutics aims for potentially disruptive $92M IPO
Amicus Therapeutics, a Cranbury, N.J., developer of drugs to treat rare genetic diseases, said it plans to raise as much as $92 million in an IPO — money that would fund its pursuit of new drugs for rare genetic diseases, a strategy could be disruptive… Continue Reading